EASL nonalcoholic fatty liver disease summit: uniting clinicians, experts, and industry
Geneva, Switzerland, 20 September 2018 - The EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit commenced today at the Starling Hotel Conference Centre in Geneva, Switzerland, attended by over 300 basic and clinical researchers, industry, and renowned specialists from around the world.
7 recent reports on obesity risks in liver disease, lifestyle intervention
Physicians and researchers have noted the increase in liver disease over the last couple decades, especially nonalcoholic fatty liver disease, correlates significantly with the increase in obesity and overweight.
Existing liver drug can help treat alzheimer’s
Research reveals that an existing drug used to treat liver disease could also be employed in Alzheimer's disease therapy. The drug "heals" malfunctioning elements at cellular level.
EASL mourns the passing of Professor Jan De Groote
Professor Jan De Groote recently passed away aged 93. He will be remembered as the first Secretary General of EASL (1966–1969) and as one of the founding fathers of “the Gnomes”, the International Liver Pathology Study Group.
New target could prevent progression of liver damage to cancer
Photo caption: Dr. Anatolij Horuzsko, reproductive immunologist in the Georgia Cancer Center and Department of Medicine at the Medical College of Georgia at Augusta University (photo credit: Phil Jones, Senior Photographer, Augusta…
More protein after weight loss may reduce fatty liver disease
Increasing the amount of protein in the diet may reduce the liver's fat content and lower the risk of diabetes in people with nonalcoholic fatty liver disease (NAFLD). The study is published…
Even light drinking may make fatty liver disease worse
(Reuters Health) - People who have fatty liver disease that wasn’t caused by heavy drinking may still need to avoid alcohol if they want to prevent their liver damage from getting worse, a Korean study suggests.